Controlling myocyte cGMP: phosphodiesterase 1 joins the fray

Circ Res. 2009 Nov 6;105(10):931-3. doi: 10.1161/CIRCRESAHA.109.209700.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism
  • Animals
  • Calcium / metabolism*
  • Calcium Signaling / drug effects
  • Calcium Signaling / radiation effects*
  • Calmodulin / metabolism*
  • Cardiomegaly / chemically induced
  • Cardiomegaly / enzymology*
  • Cardiotonic Agents / adverse effects
  • Cardiotonic Agents / pharmacology
  • Cells, Cultured
  • Cyclic GMP / metabolism*
  • Cyclic Nucleotide Phosphodiesterases, Type 1 / biosynthesis*
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Expression Regulation, Enzymologic / physiology
  • Heart Ventricles / enzymology
  • Humans
  • Isoproterenol / adverse effects
  • Isoproterenol / pharmacology
  • Male
  • Mice
  • Myocytes, Cardiac / enzymology*
  • Rats
  • Rats, Sprague-Dawley
  • Second Messenger Systems / drug effects
  • Second Messenger Systems / physiology*

Substances

  • Calmodulin
  • Cardiotonic Agents
  • Enzyme Inhibitors
  • Angiotensin II
  • Cyclic Nucleotide Phosphodiesterases, Type 1
  • Pde1A protein, mouse
  • Pde1a protein, rat
  • Cyclic GMP
  • Isoproterenol
  • Calcium